Satya Preetham Gunta

Satya Preetham Gunta

Auto-generated profile, based on publicly available information

Satya Preetham Gunta

Saint Luke's Mid America Heart Institute, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
SGSatya Preetham Gunta
Satya Preetham Gunta
RJRoopesh Sai Jakulla
Roopesh Sai Jakulla
AUAamer Ubaid
Aamer Ubaid
KMKareem Mohamed
Kareem Mohamed
ABAbid Bhat
Abid Bhat
NNNicholas Norgard
Nicholas Norgard
Obstructive sleep apnea (OSA) is one of the most common and serious sleep-related breathing disorders with a high prevalence among patients with cardiovascular (CV) diseases. Despite its widespread presence, OSA remains severely undiagnosed and untreated. CV mortality and morbidity are significantly increased in the presence of OSA as it is associated with an increased risk of resistant hypertension, heart failure, arrhythmias, and coronary artery disease. Evaluation and treatment of OSA should focus on recognizing patients at risk of developing OSA. The use of screening questionnaires should be routine, but a formal polysomnography sleep study is fundamental in establishing and classifying OSA. Recognition of OSA patients will allow for the institution of appropriate therapy that should alleviate OSA-related symptoms with the intent of decreasing adverse CV risk. In this review, we focus on the impact OSA has on CV disease and evaluate contemporary OSA treatments. Our goal is to heighten awareness among CV practitioners.

16 April 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
BSBrett W. Sperry
Brett W. Sperry
MVMary Stefanie Vamenta
Mary Stefanie Vamenta
SGSatya Preetham Gunta
Satya Preetham Gunta
RTRandall C. Thompson
Randall C. Thompson
AEAndrew J. Einstein
Andrew J. Einstein
AMA. Iain McGhie
A. Iain McGhie
Background: Essential to a patient‐centered approach to imaging individuals with chest pain is knowledge of differences in radiation effective dose across imaging modalities. Body mass index (BMI) is an important and underappreciated predictor of effective dose. This study evaluated the impact of BMI on estimated radiation exposure across imaging modalities. Methods and Results: This was a retrospective analysis of patients with concern for cardiac ischemia undergoing positron emission tomography (PET)/computed tomography (CT), cadmium zinc telluride single‐photon emission CT (SPECT) myocardial perfusion imaging, or coronary CT angiography (CCTA) using state‐of‐the‐art imaging modalities and optimal radiation‐sparing protocols. Radiation exposure was calculated across BMI categories based on established cardiac imaging–specific conversion factors. Among 9046 patients (mean±SD age, 64.3±13.1 years; 55% men; mean±SD BMI, 30.6±6.9 kg/m 2 ), 4787 were imaged with PET/CT, 3092 were imaged with SPECT/CT, and 1167 were imaged with CCTA. Median (interquartile range) radiation effective doses were 4.4 (3.9–4.9) mSv for PET/CT, 4.9 (4.0–6.3) mSv for SPECT/CT, and 6.9 (4.0–11.2) mSv for CCTA. Patients at a BMI 45 kg/m 2 compared with <20 kg/m 2 (median, 26.9 versus 2.6 mSv). After multivariable adjustment, PET/CT offered the lowest effective dose, followed by SPECT/CT, and then CCTA ( P <0.001). Conclusions: Although median radiation exposure is modest across state‐of‐the‐art PET/CT, SPECT/CT, and CCTA systems using optimal radiation‐sparing protocols, there are significant variations across modalities based on BMI. These data are important for making patient‐centered decisions for ischemic testing.

7 January 2022 in Postgraduate Medicine
Verified
Journal Article
Closed access
SGSatya Preetham Gunta
Satya Preetham Gunta
AUAin Ul-Ejaz
Ain Ul-Ejaz
AMAbigail May Murphy
Abigail May Murphy
KGKaylea May Gunn
Kaylea May Gunn
ABAmbika Bhatnagar
Ambika Bhatnagar
SASuveen Angraal
Suveen Angraal
Primary Care Physicians (PCPs) may be the first providers for the patients in a healthcare interaction, putting them in a unique position which may determine health trajectory of a patient. Assessing whether PCPs improve the overall health of a community through reducing preventable hospital stays and premature deaths may provide necessary information towards improving the health outcomes at grass roots. County-level data on the number of primary care physicians, preventable hospital stays and ‘years of potential life lost’ (YPLL) were obtained from the Physician Master File data of the American Medical Association, Centers for Medicare & Medicaid Services Office of Minority Health’s Mapping Medicare Disparities data, and Center for Disease Control and Prevention’s WONDER database, respectively. We employed linear regression model to assess the association of PCP rate with preventable hospital stays and YPLL. Preventable hospitalization rate in the United States was 6303.4 (95% CI, 6212.5-6394.3) hospitalizations per 100,00 population per year while the average YPLL across the counties in the United States was 7792.9 (95% CI, 7697.6-7888.3) years per 100,000 population. For an increase of 1 PCP in a county, around 16 hospitalizations were prevented per 100,000 population (P=0.001) each year. Furthermore, around 14 years of life were saved per 100,000 population for every additional PCP in a county across the United States (P <0.001). Higher number of PCPs in a county was associated with lower hospitalizations for preventable causes and lower premature deaths. Increasing PCPs may be important metric to improve overall health in a community.

1 January 2024 in Autopsy Case Reports
Verified
Journal Article
Open access
PDF file
UMUjjwal Madan
Ujjwal Madan
Himil MahadeviaHimil Mahadevia
Himil Mahadevia
PSParth Sharma
Parth Sharma
SGSatya Preetham Gunta
Satya Preetham Gunta
OTOssama Tawfik
Ossama Tawfik
JMJulian Magadan
Julian Magadan
Autops Case Rep, vol.14, e2024488, 2024

7 April 2026 in medRxiv
Verified
Preprint
Open access
SGSatya Preetham Gunta
Satya Preetham Gunta
DMDivyanshu Mohananey
Divyanshu Mohananey
NGNoelle Garster
Noelle Garster
CBChristopher Bennett
Christopher Bennett
SKSunaina Kalidindi
Sunaina Kalidindi
DLDavid Lewandowski
David Lewandowski
Background Cardiac MRI (CMR) is often utilized for patients with suspected cardiac amyloidosis (CA). However, data are lacking for use in patients with advanced renal dysfunction (ARD) (GFR<30 mL/min/1.73 m2, dialysis dependent, or renal transplant). This study evaluates the utility of CMR for diagnosis of CA in this population. Methods Patients with ARD who underwent CMR in a 3T field for suspicion of CA between 2010 and 2024 at our institution were included. A diagnosis of CA was made if any of the following were present a)?PYP scintigraphy grade ? 2, b) positive endomyocardial biopsy, or c) positive extracardiac biopsy with clinical features of CA. Two CMR-trained physicians independently assessed T1 relaxation time, ECV, Ti scout, LGE, and overall likelihood of CA. Results Out of the 65 patients included 14 (22%) had a diagnosis of CA. Although T1 time [1352 (1276-1428) ms] and ECV (40.3% +/- 9.1%) were elevated across the cohort, they were significantly higher in patients with CA (p<0.001 for both). Both ECV and T1 time reliably predicted CA (AUC of 0.87 and 0.88 respectively). ECV of ?45% had 75% sensitivity and 80% specificity for CA. A T1 time ? 1390 ms had 75% sensitivity and 85% specificity for CA. LGE was prevalent and was seen in 86% and 84% patients with and without CA respectively. Of the 31 patients deemed to be unlikely CA by a CMR reader, 6% had CA. However, of the 34 patients read as possible/likely CA, only 35% had confirmed CA. Conclusions In this understudied population of ARD, CMR parametric mapping exhibits high negative predictive value (NPV) for CA and improved positive predictive value (PPV) when higher cutoffs are used for T1 time and ECV. CMR reader overall impression exhibits high NPV but low PPV for CA.